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The Vitelline membrane outer layer protein 1 (VMO1) was first identified in 
the Vitelline membrane of the chicken egg. This membrane almost entirely 
protein that separates the egg white from the yolk in amniotic eggs and 
acts as the last defensive barrier between pathogens and the egg yolk 
with the developing embryo. Since its discovery in the vitelline membrane, 
VMO1 has been isolated from a number of different tissues and animals. 
The one that would appear to have the largest impact on human health 
would be its discovery in the Reissner’s membrane of mice, whose 
auditory system has high structural homology to humans. The Reissner’s 
membrane maintains the electrolyte level in the compartments of the inner 
ear as well as the resting electrochemical potential which are both critical 
for correct hearing function. 
The main aims of the research undertaken in this thesis was to 1) 
determine the tissues in which VMO1 is or is not expressed in humans 
and 2) create a genetically modified expression clone of human VMO1 to 
use in further downstream protein-protein interaction studies. Our 
hypothesis is that we can amplify VMO1 from human cell lines based on 
available bioinformatics data.  
The first objective was to determine the gene expression of VMO1 in 
multiple human cell lines. RNA was extracted from three commercial cell 
lines (list) and the integrity of RNA was confirmed by agarose gel 
electrophoresis by the observation of two rRNA bands. From this cDNA 
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was made, and PCR analysis performed to identify the expression, or not, 
of VMO1 in these tissues. Successful amplification of VMO1 from lung 
cells (A549) lead to the creation of a human VMO1 expression clone, by 
transforming competent Escherichia coli cells with ligated VMO-1 
insert/pPLUG vector. White colonies were selected for DNA extraction and 
confirmed as positive using colony PCR and agarose gel electrophoresis. 
DNA seuqencing of the positive clone confirmed the nucleotide sequence 
as VMO1. 
The second objective was to validate the commercial antibody for human 
VMO1 using physiological and immunohistochemical methodology. The 
immunohistochemistry data suggests that the VMO1 protein is a secreted 
protein since signal was detected in the P5 mouse inner ear and mouse 
adult lung. However, multiple bands were observed in the western blot. 
Futher investigation is required to validate the VMO1 antibody to 
demonstrate that it is indeed specific to recognising its target epitope. The 
production of recombinant VMO1 protein would be benefical to address 
this question. 
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1.1 Vitelline Membrane and VMO1 
The vitelline membrane is a acellular matrix consisting of almost entirely 
protein that separates the egg white (albumin) from the yolk in amniotic 
eggs. This membrane consists of two distinct major layers with the inner 
layer facing the egg yolk, and the outer facing the albumen, separated by 
a thin continuous film as shown in Figure 1. The vitelline membrane acts 
as the last defensive barrier between pathogens and the egg yolk with the 
developing embryo, and as such, has a direct effect thereupon [2-6]. The 
vitelline membrane is formed in two separate places during the process of 
egg development. The inner layer is formed first, taking place inside the 
ovary no more than 7-10 days before ovulation. The outer layer forms later 
in a funnel shaped structure called the infundibulum, which is where 
fertilisation takes place. The differing places of development give the two 
layers a rather different protein composition and as such distinctly different 
properties.  
1 Literature Review 
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The inner layer is comprised of at least four different glycoproteins (GPI, II, 
III and IV) and an ordered structure similar to what is seen in connective 
tissues. The inner membrane is the homologous structure to the 
mammalian zona pellucida, and as such contains zona pellucida proteins 
also, notably ZPC/ZX3, ZPI and ZPD. As in the zona pellucida, this layer is 
involved in the fertilisation process acting primarily as a barrier to sperm. It 
has also been theorised as an anchor for other cells to adhere to in order 
to avoid polyspermy, and to facilitate same-species fertilisation only [7, 8]. 
The outer layer is structurally less ordered, and is composed of several 
overlapping sub layers. These sub layers are primarily constructed of fine 
fibrils, interspersed with a high quantity of bound protein. The composition 
of the outer layer mostly comprises of the macromolecule ovomucin 
constituting 43% with the soluble proteins lysozyme, vitelline membrane 
outer layer protein 1 (VMO1) and vitelline membrane outer layer protein 2 
(VMO2) (which is now known as β-defensin 11 [9]) bound to it [4, 5]. 
Figure 1: Cross section of the chicken egg to illustrate the structure of the chicken egg and the vitelline 
membrane with its three layers; the outer vitelline layer, the thin continuous layer and inner perivitelline layer 
next to the egg yolk (adapted from http://shelka78.files.wordpress.com/2011/12/egg_cross_section.png) 
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Lysozyme has the second highest abundance at 32%, with the VMO 
proteins constituting 20% and 5% respectively to the protein content of the 
outer layer [10].  
The vitelline membrane is present in its complete form at the time of 
fertilisation in the infundibulum. As with the zona pellucida in mammals it 
acts as a barrier to sperm, and has been hypothesised as an anchor for 
other cells to adhere to in order to avoid polyspermy, and to facilitate 
same-species fertilisation only although this is mostly done by the inner 
layer [7].The vitelline membrane does possess qualities that are desirable 
in a commercial context for its ability to act as a standard for the quality 
indicator for the shelf life of hens eggs. Whilst the vitelline membrane only 
persists for four days in a fertilised egg, it has the ability to last a lot longer 
in the unfertilised egg depending on its storage conditions [3, 4]. 
Understanding how the membrane degrades might better help to prolong 
the shelf lives of eggs, and it is due to this commercial interest that the 
proteins of this outer layer have been looked into. The protein VMO1 is 
therefore of interest being a major protein constituent in the outer layer, 
although its function remains elusive. 
1.2 VMO1 Structure 
Protein structure is a tool that gives us a snapshot of the resulting shape 
of the protein, and the internal forces that work upon it. Structural 
homology might also be able to give an indication of potential function of a 
protein as well. The structure of proteins can be described in many levels, 
with the primary structure simply being the amino acid sequence. The 
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secondary structure is how the primary structure interacts with itself 
though noncovalent bonds and van der Waals forces. These secondary 
structures determine whether there will be α-helices, β-sheets or turns in 
the protein, all of which have structural importance to the functioning 
protein. Tertiary structure is how the secondary structure folds into a three 
dimensional (3D) shape. This happens usually through folding to form a 
hydrophobic core through the use of salt bridges, hydrogen and ionic 
bonds alongside post translational modifications. These all work together 
to make a distinct shape of a protein, as well as to determine the shape 
and properties of any active site it may possess, and how it interacts with 
other proteins [11]. 
 
The primary structure of chicken VMO1 is 183 amino acids long, including 
a 20 amino acid signal peptide leaving a 163 amino acid long mature 
protein. Signal peptides typically only appear on proteins targeted to a 
specific area, either to be secreted out of the cell, or to a specific organelle. 
This alone may signify that VMO1 is a secreted protein, or highly 
specialised within the cell. In addition there is no methionine (Met) in the 
protein, which would indicate secretion and post translation modification to 
the N-terminal of the mature protein. Chemically, VMO1 has a calculated 
mass of 17,979 Da and an isoelectric point of 10, which is only slightly 
lower than that of lysozyme which has made it difficult to distinguish in 
past studies. The amino acid sequence is rich in glycine (Gly) and serine 
(Ser) as well as the essential amino acids arginine (Arg), lysine (Lys) and 
histidine (His). 
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The amino acid sequence of VMO1 contains a thrice repeated amino acid 
motif of ~53 residues that gives the protein a threefold internal symmetry. 
This repeat forms a series of β-strands that lie to form a Greek key motif. 
This motif is characterised by three antiparallel β-sheets connected by 
short turning strands of two to five amino acid (usually containing Gly or 
Pro) to make β-hairpins with a fourth β-sheet looping back to lie 
antiparallel to the first sheet. The resulting structure resembles the 
decorative key motif found on many pottery pieces and jewellery from the 
Grecian culture, hence the nomenclature.  
  
The three repeats of the β-sheets that make the three Greek key 
structures are the only secondary structures that contribute to the structure 
of the VMO1 protein, and by merit of being comprised almost solely of β-
Figure 2: Diagram to show the Greek key motif. (A) The ornamental Greek key design from 
whence the structure name derives (adapted from 
http://www.clker.com/cliparts/9/x/v/v/l/v/greek-key1.svg). (B) The four possible 
orientations of the structure overlaying the ornamental motif (adapted from 
http://wbiomed.curtin.edu.au/biochem/tutorials/prottute/sheetsuperfigs.htm). (C) The 
three repeats of the Greek key structure of hen VMO1 with the bolder grey lines showing 
disulphide bonds between them [2]. 
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sheets VMO1 is categorised as a β protein. This classification groups it 
with other proteins such as the β-barrel of human retinol binding protein, 
the β-propeller protein found in the influenza viral envelope and the 
immunoglobulin fold of antibodies. The beta sheets fold into a triangular 
prism shape, to form the tertiary, 3D crystal structure. Each side of the 
prism is one of the Greek key β-sheets, with the disulphide bonds at the 
wide bottom end of the prism, and long flexible loops at the ‘point.’ The 
base of the prism has an overall positive charge, with the disulphide bonds 
that are the sole bonds forming the structure as there are no other 
interactions between the beta sheets. This is in contrast with the flexible 
loops which are overall negatively charged, and form a cavity that is 
likewise negatively charged. This cavity is similar in size to that of 
lysozyme, a well-known hydrolase of polysaccharides and is characteristic 
of many proteins consisting of Greek key motif structures, which gain 
functional variability from such loops, and the cavities thus generated are 
of a size to fit ligands such as oligosaccharides. This would appear to 
indicate that VMO1 should have an enzymatic hydrolysis or recognition 
activity on a saccharide substrate which would rely on the acidic residues 
that give the cavity its negative charge, namely due to containing two Asp 
residues frequently involved in hydrogen binding between proteins and 
sugar [2].  
1.3 VMO1 in Other Tissues 
Since its discovery in the vitelline membrane VMO1 has been isolated 
from the egg white [12, 13] and egg shell matrix [14]. Its discovery has not 
been limited to within the chicken either, with VMO1 homologues having 
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been identified in the genomes and tissues from other animal species. It 
has been genetically confirmed to exist in the green anole lizard [15], and 
has been identified through proteomic studies to be in the tissues of other 
animals. Notably vmo1 has been found to be expressed in the tear film of 
camels and sheep [16, 17], the maxillary venom gland of Philodryas 
olfersii (South American green racer) [18], and the Reissner’s membrane 
in mice [1]. 
Firstly the tear film contains a number of lipid, protein and mucous 
componants which act together to form a barrier between the delicate 
surface of the eye and the outside world. The tear film also acts to nourish 
and lubricate the surface, and is stabilised by the proteins it contains. 
These proteins, whilst contributing to the integrity of the tear film also play 
a large role in modulating the eyes wound healing ability and protection 
from pathogens. Therefore they are a good marker for studying 
pathophysiological mechanisms and ocular surface diseases, as well as 
potentially being used as a marker for ocular health. Several environmental 
risk factors such as relative humidity, temperature, air velocity, and air 
particles alter the composition of the tear film, which may cause and or 
exacerbate the development of ocular discomfort as eye irritation 
symptoms. Dry eye diseases have also been reported to be linked to other 
environmental factors such as windy weather, long hours of sunlight and 
UV radiation, and several types of conjunctivitis can be linked to the 
seasonal changes of these environmental factors. In the camel tear film 
VMO1 was shown to increase significantly during the summer months 
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indicating that its function, whatever that may be, is important for the 
regulation of the tear film under harsh conditions [17]. 
Secondly snake venom has the primary role of assisting prey capture, 
whether by slow death or paralysis of the prey. As such, there is natural 
selection pressure on both the prey and the snake, with the prey 
developing tolerance to the venom, and the snakes having evolutionary 
pressure to vary or optimise the toxins in their venom to circumvent the 
tolerance. The production of venom starts with the expression of a gene 
for a normal body protein that undergoes duplication and the copy 
expressed solely in the venom gland. These proteins are often cysteine 
rich to confer stability and already bioactive, or important regulatory genes, 
and the duplicates become mutated through random mutation, unequal 
crossing over or gene conversion and gain a new function. This process is 
called neofunctionalisation. Despite knowing that this occurs, few 
proteomic studies of the venom glands of toxic snakes focus on new 
venom scaffolds, but instead on new isoforms of existing ones. One study 
investigated new scaffolds to study toxin evolution over time, and identified 
the expression of VMO1 within the venom gland of P. olfersii [18]. No 
function was determined for VMO1, nor was it analysed in other tissues to 
determine if this is a duplicate and thus new venom scaffold. However, 
since it is expressed in the venom gland then it supports the idea that 
VMO1 is a secreted protein. 
Thirdly the inner ear is comprised of the cochlea and vestibular which both 
play an important role in the translation of sound into nerve impulse. The 
organ of Corti, located within the cochlea is the end point for sound, and is 
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structurally comprised of three rows of sensitive but vulnerable outer hair 
cells, and one row of less sensitive and less vulnerable inner hair cells. It 
is attached to the basilar membrane, and partially covered by the tympanic 
membrane[19]. The cochlea itself contains three chambers of differing 
ionic strengths, the scala tympani, and scala vestibuli which both contain 
perilymph, and the scala media containing endolymph. Perilymph is similar 
to blood plasma with a high concentration of Na+ at 140mM and a low 
concentration of K+ at 4mM, whilst endolymph has the opposite with a high 
concentration of K+ at 150mM and low Na+ at 1mM making it more similar 
to intracellular fluid [20]. These two fluids maintain a resting 
electrochemical potential of between +80 - +100mV relative to the interior 
of the hair cells, important for their continued correct function [21]. The 
endolymph filled scala media and perilymph filled scala vestibuli are 
separated by the Reissner’s membrane, a double layered membrane 
which acts as a diffusion barrier between the two differing electrochemical 
fluids. The Reissner’s membrane acts as a facilitator of electrolytes 
between the two fluids maintaining their composition, and through that the 
resting electrochemical potential that is critical for correct hearing function 
[22]. Therefore it is of interest to investigate VMO1 in the inner ear, and 
specifically these structures, in order to better understand the molecular 
mechanisms of hearing. However, the inner ear is difficult to study and it is 
only through the use of animal models that it can be looked at in any great 
depth.  Using a mouse model, RNA transcripts for Vmo1 were obtained 
from the inner ear, and the Vmo1 gene was shown to be localised to the 
Reissner’s membrane using in situ hybridisation. Such specific localisation 
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would appear to indicate a significantly important function for Vmo1 in the 
mouse inner ear, especially Vmo1 in the mouse inner ear, especially as 
Vmo1 gene expression was not found in 87 tissues included in the Mouse 
Reference Transcriptome or reverse transcribed in adult liver, kidney, 
pancreas, retina, brain, and testes [1].  
 
Despite having an unknown function VMO1 seems to play an important 
role in all of the tissues that it appears in, being of either high abundance 
as in the vitelline membrane and tear film, or being highly localised, as 
with the Reissner’s membrane in mice. Being able to elucidate a function 
for this protein may help with the understanding of key mechanisms, and 
may be able to confer information about the pathophysiology of some 
Figure 3: Diagram showing the different parts of the ear. (1) Shows the full human ear, which shares a 
high homology to the mouse ear, with the outer, middle, and inner ear shown as well as a close up of 
the inner ear (adapted from https://www.health.ny.gov/publications/4815/ and 
http://www.earsite.com/what-is-acoustic-neuroma). (2) A cross section of the cochlea showing the 
important structures therein (adapted from 
http://download.videohelp.com/vitualis/med/diagram_of_cochlea.htm). (3) In situ hybridisation of the 
cross section of a P5 mouse cochlea using a radioactively labelled Vmo1 antisense probe which binds to 
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diseases. In the next section, VMO1 and its potential in humans will be 
reviewed.  
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With the implication that VMO1 has a significant role in the tissues it is 
identified in, then VMO1 could potentially be a candidate for a 
pathophysiological indicator of disease, particularly in humans. Whilst it 
was not found in the tear film of humans [16], the high level of structural 
homology between the mouse and human ear could mean that the high 
specificity of Vmo1 in the mouse Reissner’s membrane suggests a 
significant role for hearing. As such, VMO1 would be a suitable candidate 
protein for hearing loss and balance disorders caused within the inner ear. 
In addition, it could provide screening opportunities for some disorders that 
are difficult to diagnose. 
However, before being able to attribute any disease causation by VMO1, a 
function must be elucidated. Even so, there is little known about VMO1 in 
regards to human expression beyond not being found in tear film [16], and 
that it has been found in very low abundance within human urine samples 
which would signify again that VMO1 is a secreted protein [23].  
A bioinformatics approach is able to answer a few questions about human 
VMO1. Firstly VMO1 is located on human chromosome 17 p13.2, and 
contains four mRNA transcript variants, ranging from 669bp to 821bp long. 
Three out of the four transcripts contain three exons, with no differences 
between any transcripts at the first exon, and the majority of the variation 
in the second. Indeed, transcript 2 has the longest exon 2, whilst transcript 
variant four lacks exon two entirely. Exon three is identical throughout the 
2 VMO1 in humans 
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transcripts except for variants 3 and 4, which lack the first base, with all 
sequences being obtained from the nucleotide database of the National 
Centre for Biotechnology Information (NCBI) website. Appendix three 
shows the alignments.  
Expressed sequence tag (EST, retrieved from the Unigene database 
http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?ORG=Hs&CID=122561&M
AXEST=37) data having been generated over a number of tissues through 
both RNA sequencing and microarray technology. ESTs are short 
subsections of complementary DNA (cDNA) that can be used to identify a 
gene. RNA sequencing uses Massively Parallel Signature Sequencing 
(MPSS) to generate libraries of mRNA transcripts in order to quantify and 
identify them. It works by tagging PCR products amplified for the cDNA 
made from mRNA transcripts, and amplifying them before being attached 
to microbeads and sequenced on a flow cell and the sequences analysed 
[1]. Microarray on the other hand uses short sections of nucleotides to 
hybridise the cDNA to a biochip which then undergoes sequencing to 
measure the expression levels of a gene. Through the use of both these 
technologies, the EST library shows that VMO1 is potentially expressed in 
a number of tissues (Table 1). 
Human Tissues 
 
Methodology 
Cerebellum, frontal lobe, heart, kidney, 
liver, testis 
RNA Sequencing 
 
Adipose, blood, breast, bronchus, colon, 
conjunctiva, frontal lobe, fertilised oocyte, 
liver, lung, myometrium, nasopharynx, 
nose, pituitary, prostate, putamen, vagina, 
trachea, temporal lobe, spleen, skin, 
skeletal muscle, sinus, retina 
 
Microarray 
 
Table 1: EST data for VMO1 
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2.1 Aim, Hypothesis and Objectives 
2.1.1 Aim 
The main aims of the research undertaken in this thesis were to 1) 
characterise tissues in which VMO1 is or is not expressed in humans. 2) 
To create a genetically modified expression clone of human VMO1 to use 
in further downstream protein-protein interaction studies. 3) To validate a 
VMO1 antibody for use in imunohistochemistry. 
2.1.2 Hypothesis 
EST data shows that there are a number of tissue types in which VMO1 is 
expressed. Our hypothesis is that we can amplify VMO1 from human cell 
lines of these tissues. 
2.1.3 Objectives 
The first objective was to determine the gene expression of VMO1 in 
multiple human cell lines using the following molecular methods to: 
a) Culture human cell lines under physical containment level two (PC2) 
conditions; 
b) Extract mRNA and convert to cDNA; and 
c) Use polymerase chain reaction (PCR) to amplify VMO1 transcripts. 
The second objective was to create a human VMO1 expression clone 
using the following molecular methods to: 
a) Prepare Escherichia coli (E. coli)  competent cells; 
b) Ligate VMO1 PCR product from above into an expression construct; 
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c) Transform construct into competent E. coli cells; 
d) Extract construct DNA and amplify VMO1; and 
e) Sequence the PCR product to verify it is VMO1. 
The third objective was to validate the antibody, using the following 
physiological and immunohistochemical methods to: 
a) Dissect organs from deceased mice and prepare protein lysates of 
tissue for western blot analysis or tissue for histology; 
b) Embed organs in both optimal cutting temperature media (OCT) 
and paraffin for sectioning on the cryotome/microtome respectively; 
c) Test VMO1 antibody against housekeeping antibodies using 
immunohistochemistry; and 
d) Analyse VMO1 binding and background using fluorescent 
microscopy. 
This data will allow us to begin to address the question of where VMO1 is 
expressed in humans, as well as to validate the commercial VMO1 
antibody. In addition the immunohistochemistry may tell us whether VMO1 
protein is secreted. Additionally this research will also allow for the future 
study of the human VMO1 protein, and the properties it has through the 
development of a recombinant human VMO1 expression clone. 
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Unless otherwise stated all processes were carried out within the C.2.03 
Molecular Genetics Lab at the University of Waikato, Hamilton, New 
Zealand. All sequencing was performed at the Waikato DNA Sequencing 
Facility at the University of Waikato. All solutions were made up using 
autoclaved 15-18 megohm-cm double distilled deionised water (mQH2O) 
(Barnstead double distilled/deionisation system) except for RNA work 
where mQH2O was further treated with 0.1% Diethylpyrocarbonate 
(DEPC). All chemicals and solvents (salts, buffers, organic solvents,) were 
obtained from Sigma-Aldrich® Co and all molecular biology reagents 
(enzymes and buffers) were obtained from Invitrogen unless otherwise 
stated. All experiments were carried out aseptically on bench tops cleaned 
with 70% ethanol, and in the case of RNA work, also wiped with RNA 
Away™ decontamination reagent supplied by Ambion®. All glassware was 
washed in the dishwasher and then autoclaved before use. All solution 
and buffer recipes can be found in Appendix one. 
3.1 Preparation of VMO1 Recombinant DNA 
Below is detailed all methods used during the process of creating 
recombinant DNA for the study of VMO1. Recombinant DNA allows us to 
clone the VMO1 DNA into a bacterial plasmid vector, once the mRNA has 
been extracted from tissue samples. Our sources for the mRNA in this 
study are human cell lines that have been grown in DMEM + glucose and 
penicillin-streptomycin antibiotic. We choose to use the mRNA from the 
3 Materials and Methods 
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cells, as opposed to DNA, for the additional information it can tell us about 
whether VMO1 is expressed in these tissue types. The mRNA is then 
converted to cDNA, and undergoes PCR to check the quality and size, 
before being ligated into T t-tailed vector and transformed into competent 
bacterial cells through either electroporation or heat shock. Once 
incorporated, the competent cells can be prepared in either a mini- or 
maxi-prep and the plasmid isolated for direct use, or for incorporation into 
an expression vector for protein studies. 
3.1.1 General Materials 
Unless stated otherwise these statements hold true for methods outlined 
below. All RNA centrifugation was carried out using an Eppendorf bench 
top centrifuge model 5424R, whilst all other centrifugation was carried out 
on an Eppendorf bench top centrifuge model 5415R both with a maximum 
speed of 16.1xg. Sterile aerosol tips were Sorenson™ low binding 
MultiGuard aerosol barrier tips supplied by Sigma-Aldrich® Co, else 
MULTIMAX Low Retention Pipet Tips from BioExpress and used with 
Eppendorf auto pipettes. All 1.5mL and 2mL micro centrifuge tubes were 
supplied by Raylab New Zealand ltd, whilst all 0.6mL tubes were supplied 
by Axygen®. All falcon tubes were Cellstar® branded supplied by Greiner 
Bio-one. Nanodrop qualification and quantification was carried out using a 
Thermo Scientific™ Nanodrop 2000 spectrophotometer and 
accompanying software. Agarose gel electrophoresis was carried out 
using Hydragene HyAgarose™ agarose and TAE buffer, run at 90V for 30 
minutes. All thermo cycler incubations were carried out in an Eppendorf 
thermo mixer comfort machine, while PCR was carried out in a Bio-Rad 
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Laboratories Inc. T100 thermal cycler. All electroporation was carried out 
using a Bio-Rad Laboratories Inc. Gene Pulser® and Pulse Controller set 
at 25 capacitance, 200 resistance, and 250 voltage. 100bp DNA ladder 
was sourced from Solis Biodyne. All plates were made using LB+ agar 
media unless stated otherwise. 
3.1.2 In Vitro Cultivation of Human Cells 
Frozen cells were obtained from storage in the -80°C Cell Culture 
Inventory, Department of Biological Sciences, University of Waikato. Cells 
were revived in DMEM + glucose and penicillin-streptomycin antibiotic and 
grown in a 37°C incubator at 5% CO2 by Kirsty Mayall. Cell lines used 
were the lung carcinoma A549 cells and white blood leukocyte THP-1 cells 
donated by Gregory Jacobson, and cervical cancer HeLa cells donated by 
Ryan Martinus. A cell concentration of 106 was required for efficient RNA 
extraction. 
3.1.3 RNA Extraction from Human Cell Lines 
All RNA work was performed on a dedicated RNase free bench, with its 
own dedicated filter tips for auto pipettes to be used for RNA work only. All 
reagents used are stored there for RNA use only to decrease RNase 
contamination. Bench and instruments were wiped down with RNA 
Away™ decontamination reagent before and after use to also minimise 
RNase contamination. 
RNA extraction was performed on all cell lines. All media was first 
removed from T25 tissue culture flasks by aspiration and cells were 
washed with 1-2mL 1x PBS solution. The PBS was then aspirated off. 
 
31 
500µL GITC was then added over the surface of the cells in order to lyse 
them, and the liquid pipetted up and down until gluggy, then transferred to 
a 1.5mL micro centrifuge tube, and 1/10volume of 2M sodium acetate was 
added in order to precipitate RNA. The tube was mixed thoroughly by 
inversion for 15 seconds. 500µL phenol (pH4) was added in fume hood, 
and shaken vigorously for 1 minute, before being placed on the rotating 
wheel for 5 minutes. Phenol is important for removing protein, and pH4 
specifically keeps the RNA in solution as opposed to pH8 for DNA. Further 
protein removal was facilitated by adding 100µL bromochloropropane 
(chloroform could be substituted here, but is more toxic) and emulsified 
(shake vigorously for 15 seconds) before being placed on a rotating wheel 
for 5 minutes. The sample was then centrifuged at maximum speed for 
10minutes at 4°C. The aqueous layer was then transferred to a new 1.5mL 
tube. The organic layer can either be discarded, or used for protein 
extraction.  
One tenth volume of 2M sodium acetate was added to the transferred 
aqueous layer and mixed thoroughly by inversion before adding 500µL 
phenol (pH4) in fume hood. Also in fume hood,  200µL of chloroform was 
added to aid in further protein removal, for the purest RNA. The sample 
was then emulsified for 1 minute, before being placing on the rotating 
wheel for 5 minutes then centrifuged at maximum speed for 10minutes at 
4°C. The aqueous layer was again removed to new tube. 
An equal volume of ice cold isopropanol was added to the sample, and 
incubated at -20°C for 10minutes. Centrifuged at maximum speed or 
10minutes at 4°C, then removed and discarded the supernatant. The 
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pellet was washed with 500µL of 60% ethanol to remove excess salts and 
dehydrate pellet. The centrifugation was repeated, and all ethanol 
removed. The pellet was air dried for 5 minutes before being resuspended 
in 30µL DEPC treated water. The RNA concentration and quality were 
measured on a 2% agarose gel. The sample was then either used directly 
in downstream applications or stored at -80°C. 
3.1.4 RNA Agarose Gel Electrophoresis 
Quality and concentration of RNA was determined through comparison to 
a 100bp ladder on a 1% agarose gel. 
Whilst the nanodrop also quantifies the RNA, and can show the 
contamination from carry over solvents or protein, the agarose gel is a 
better indication of whether the quantification is true of the RNA or is also 
measuring DNA, as well as what condition the RNA is in. Ideally when run 
on a 1% agarose gel, pure RNA would show two distinct bands for the 16S 
and 18S ribosomal bands and little else. Any background smear would 
indicate that there is degradation of the RNA and a bright band near the 
top by the wells indicates genomic DNA contamination. 
3.1.5 cDNA Synthesis 
The Tetro cDNA Synthesis Kit was supplied by Bioline Australia and used 
according to the manufacturer’s directions. In brief, a master mix was 
prepared in a PCR tube according to Table 2, and mixed by pipetting, and 
spun briefly to ensure all contents get to the bottom of the tube. 
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Total RNA nµl 
Primer: Oligo (dt)18, 
Random hexamers, or 
gene specific 
1µl 
10mM dNTP mix 1µl 
5x RT buffer 4µl 
Ribosafe RNase 
Inhibitor 
1µl 
Tetro RT (200u/µl) 1µl 
DEPC treated water Up to 20µl 
                           Table 2: Primer mix for cDNA synthesis 
Samples were incubated at 45°C for 30 minutes in a thermo mixer to allow 
reverse transcription of the RNA template. If random hexamers were used 
they were incubated for an additional 10 minutes 25°C prior to the 45°C 
incubation to allow the primers to anneal to their target sequence. The 
reaction was then terminated by heat inactivation with an incubation of 
85°C for 5 min, followed by chilling on ice for 2 minutes. The cDNA sample 
was then either used immediately for PCR and downstream applications 
or stored at -20°C. 
3.1.6 Primer Design 
Primers for PCR were designed using the mRNA sequence for transcript 
variant 1 accessed from the NCBI website. The primer design tool, also 
from their website was used to generate the primers, and only those that 
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hit VMO1 only, and were exon-exon spanning were selected. Exon-exon 
spanning is required to be able to distinguish between products that come 
from the cDNA made from VMO1 mRNA and genomic DNA. 
3.1.7 PCR 
PCR was carried out on all cDNA samples to ensure that the fragments 
were of the right size for VMO1 before any further downstream 
applications were carried out. Positive controls used were primers for the 
housekeeping genes β-actin and Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). 
A master mix was prepared as in Table 3 using sterile aerosol tips to avoid 
contamination of reaction. 15µL of the master mix was added to 0.6µL 
PCR tubes. To this was added 2µL of both forward and reverse primers 
(Table 4), from 2.5mM working stocks, and 1µL template DNA before 
being placed in the PCR machine and run according to Table 5. 
10X Buffer 2µL 
25mM MgCl2 1.2µL 
10mM dNTPs  0.4µL 
5U/µL HOT FIREpol® taq 
polymerase (Solis Biodyne, 
Estonia) 
0.1µL 
MilliQ H2O 11.3µL 
                    Table 3: PCR master mix 
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GAPDH forward CAAGAAGGTGGTGAAGCAGG 
GAPDH reverse GATGGTACATGACAAGGTGC 
VMO1 forward 1 GGCCTGATTCACAGACGCTA 
VMO1 forward 2 GCCTGAGATGTGTCCCGATG 
VMO1 reverse CTCACTCCATTCGCCCCAGC 
                      Table 4: Nucleotide sequence of primers.  
 
95°C initial activation 15 minutes 
95°C activation 20 seconds 
60°C annealing 30 seconds      
72°C extension 45 seconds 
72°C final extension 5 minutes 
                    Table 5: PCR cycling conditons  
3.1.8 Ligation 
Ligation was carried out using the pLUG-Prime® TA-cloning kit from 
iNtRON Biotechnology, Korea, and used according to manufacturer’s 
instructions. The insert to vector ratio was figured out using Equation 1. 
Briefly, a master mix was set up as seen in Table 6 in a 0.6µL PCR tube. 
The reaction was mixed by pipetting, and briefly spun to ensure all 
contents at the bottom of tube. Reactions were left at 4°C overnight to 
ensure maximum ligation efficiency. Controls were set up using the 
                                                               GAPDH product 
length is 412bp, VMO1 forward 1 with the reverse is 354bp 
andVMO1 forward 2 with the reverse is 184bp based on transcript 
variation 1. 
50ng X PCR product size 
(bp) 
Vector size (bp) 
ng PCR product= 
=required= 
X molar ratio 
x30 cycles 
Equation 1: Insert to vector ration equation 
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positive supplied by the kit, and a negative containing no PCR products. 
Reactions were transformed as outlined in the next section the next day. 
 
 Experimental Positive control Negative control 
10x Ligation 
buffer A 
1µL 1µL 1µL 
10x Ligation 
buffer B 
1µL 1µL 1µL 
TA-cloning 
vector 
2µL 2µL 2µL 
PCR product xµL (see 
equation) 
- - 
T4 DNA ligase 1µL 1µL 1µL 
Control DNA - 3µL - 
Deionised water XµL (to make 
10µL reaction) 
XµL (to make 
10µL reaction) 
XµL (to make 
10µL reaction) 
Table 6: Ligation master mix 
3.1.9 Transformation 
3.1.9.1 Electrocompetent cells 
All electroporated ligation was into the E. coli DH5α cell line sourced from 
the Department of Biology (University of Waikato, New Zealand). 
All E. coli DH5α cells are stored in 50µL aliquots at -80°C, and are thawed 
completely on ice before use. A 50µL aliquot of cells is then transferred 
into an electroporation cuvette. To this, 1µL of the ligation mix was added, 
 
37 
and the cuvette placed in the electroporator. Once electroporated, 1mL of 
pre-warmed LB+ broth was added into the cuvette, pipetted up and down 
then all liquid removed to a 1.7mL microcentrifuge tube. Tube was placed 
in a 35°C shaking incubator for 1 hour, before 100µL of the mix was 
spread on an XGAL/IPTG plate, which allows for the selection of blue and 
white colonies to screen for transformations containing the insert, and 
incubated at 37°C overnight. 
3.1.9.2 Chemically competent cells 
Chemical transformation was carried out using E. cloni® 10G chemically 
competent cells, sourced from Lucigen according to the manufacturer’s 
instructions. They were stored at -80°C until use, and thawed completely 
on ice, and 40µL aliquoted into a PCR tube. 
Firstly, the ligation reaction was heat inactivated by incubation the reaction 
at 70°C for 15 minutes prior to transformation. 1-4µL of heat inactivated 
ligation reaction was then added to the PCR tube containing 40µL of cells 
and stirred briefly with pipette tip. The mix was ten incubated on ice or 30 
minutes, followed by heat shock in a water bath at 42°C for 45 seconds 
before being returned to ice for 2 minutes. 1mL recovery medium was then 
added to the cells, and incubated at 37°C for 1 hour, shaking at 250rpm, 
before being spread on XGAL/IPTG plates and incubated overnight at 
37°C. 
3.1.9.3 Mix and Go competent cells 
The Mix & Go E. coli Transformation Kit and Buffer Set were supplied by 
Zymo Research and used as per manufacturer’s instructions. Briefly. The 
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competent cells were prepared by growing E. coli cells in Zymobroth™ 
shaking at 250rpm until they reached an optical density between 0.4 and 
0.6 at 600nm. Cells were placed on ice for 10 minutes, then  centrifuged at 
4°C at 1600xg for 10 minutes. Supernatant was removed and pellet 
resuspended in 5mL ice cold 1x wash buffer (supplied). Centrifugation was 
repeated and supernatant discard. 5mL ice cold 1x competent buffer 
(supplied), aliquoted and stored at -80°C for future use, or used straight 
away for transformation. 
Trnasformation with these competent cells was done by adding 5µL of 
plasmid DNA to an aliquot of thawed 100µL of Mix & Go cells. These were 
then left on ice for one minute before being plated onto XGAL/IPTG plates 
and incubated overnight at 37°C.  
3.1.10 Colony PCR 
Colony PCR was performed on randomly selected white colonies to 
screen for the presence of VMO1. PCR master mix was set up as per 
Table 2, and 2µL of both forward and reverse primers added. Colonies 
were then picked with a sterile wooden toothpick and dipped into the PCR 
mix before being streaked on a plate which was left to incubate overnight 
at 37°C. 
PCR was then performed as per section 3.1.7. The results were run on a 2% 
agarose gel against a 1kb ladder. 
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3.1.11 Plasmid Isolation 
Plasmids were sourced from sourced from the Department of Biology 
(University of Waikato, New Zealand) and the alkaline lysis isolation 
protocol used was sourced from the Plant Biotechnology Resource & 
Outreach Centre at Michigan State University. 
Firstly, 2ml of Luria broth (LB) was inoculated with a single bacterial colony 
obtained from the transformed XGAL/IPTG plates, and incubated 
overnight at 37°C at a vigorous shaking speed (approximately 360rpm or 
higher). Samples were then centrifuged at 10,000xg for 5 minutes at room 
temperature to pellet culture, the supernatant was discarded. The pellet 
was resuspended pellet using 200µL of ice cold Solution I, to lyse the 
bacterial cell wall, and 20µg/ml RNase A, to remove RNA, followed by 
vortexing for 1 minute to mix. 200µL of Solution II was added and mixed 
thoroughly by gentle inversion to disrupt the protein-protein and lipid-
protein complexes prior to incubation at room temperature for 5 minutes. 
Add solution III to precipitate the chromosomal DNA, protein/membrane 
complexes before centrifuging the sample at full speed for 5 minutes at 
room temperature and the supernatant transferred to a new 1.7mL 
microcentrifuge tube. The DNA was precipitated by adding 0.7 volumes of 
ice cold 100% isopropanol to the transferred supernatant and mixed 
thoroughly by gentle inversion before being incubated at room 
temperature for 5 minutes. The sample was then centrifuged at full speed 
for 10 minutes at room temperature and the supernatant discarded. The 
pellet was then resuspended in  200µl TE buffer. 
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200µl of 1:1 phenol:chloroform ph8, (to optimise for DNA) was added to 
the sample in the fume hood and mixed well by inversion for 5 minutes at 
room temperature. The sample was then centrifuged at full speed for 5 
minutes, also at room temperature and the supernatant transferred to a 
new 1.7 microcentrifuge tube. 
To the transferred supernatant 0.1 volumes of 3M sodium acetate and 2.5 
volumes of 100% ethanol were added and incubated at -20°C for 15 
minutes. The sample was then centrifuged at full speed for 10 minutes at 
4°C and the supernatant discarded. The remaining pellet was then 
washed with 500µl ice cold 70% ethanol before being centrifuged at full 
speed for 5 minutes at 4°C. The supernatant was then completely 
discarded and the pellet left to air dry for 5minutes at room temperature 
before being resuspended in 20µl TE buffer. The DNA concentration and 
quality were measured on both nanodrop and agarose gel. The sample 
was then either used directly in downstream applications or stored at -
20°C. 
3.1.12 Zyppy™ Plasmid Miniprep Kit 
The Zyppy™ Plasmid Miniprep Kit was used to isolate plasmid as a 
comparison to the longer method outlined above. The kit was used 
according to the manufacturer’s instructions. Briefly 600 μl of bacterial 
culture grown in LB medium to was added to a 1.5 ml microcentrifuge 
tube and 100 μl of 7X Lysis Buffer (Blue)1was added. Tube was mixed by 
inverting the tube 4-6 times, and the solution changing from opaque to 
clear. 350 μl of cold Neutralisation Buffer (Yellow) was added and mixed 
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thoroughly. The sample will turned yellow when the neutralization was 
complete and formed  a yellowish precipitate. The sample was inverted an 
additional 2-3 times to ensurecomplete neutralisation before being 
centrifuged at full speed for 4 minutes. The supernatant was transferred 
into the provided Zymo-Spin™ IIN column.The column was placed into a 
provided Collection Tube and centrifuged for 15 seconds and the flow-
through discarded and the column placed back into the same tube. 200 μl 
of Endo-Wash Buffer was added to the column and sample was 
centrifuged for 30 seconds. 400 μl of Zyppy™ Wash Buffer was then 
added  to the column and centrifuged for 1 minute. The column was then 
transferred to a clean 1.5 ml microcentrifuge tube, and 30 μl of Zyppy™ 
Elution Buffer 2 was added directly to the column matrix and let stand for 
one minute at room temperature before a final centrifugation for 30 
seconds to elute the plasmid DNA. 
3.1.13 Restriction Digest 
The restriction digest was carried out using restriction enzymes and their 
reagents sourced from New England Biolabs. 
1µL of DNA was added to a mixture of 1-2µl each of the restriction enzyme 
(2µL if only one enzyme used, or 1µL each of two enzymes), 10xBSA, and 
buffer 4 and made up to a 10µL reaction with 5µL of mQH2O. This was 
then incubated overnight at 37°C in a thermomixer at 400rpm. A negative 
control was prepared for each sample also, where the enzyme was 
replace with 2µL of mQH2O. 
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3.1.14 Nanodrop and DNA Agarose Gel Electrophoresis 
The quality and concentration of DNA can be determined through both 
varying wavelengths of light with Nanodrop and comparing to a 1kb ladder, 
but on a 2% agarose gel. 
TE buffer was used as the Nanodrop blank. 2µL was placed on the stage 
after washing with double distilled H2O and a Kimberly-Clark® Kimwipe, 
and the arm placed down. Blank measurements were set, then using a 
Kimwipe the TE buffer was carefully removed from the stage and replaced 
with 2µL of DNA sample. The arm was placed down again, and the 
sample recorded. Of special note are the absorbance readings of 230nm, 
260nm and 280nm. These measure organic solvents, nucleic acids and 
proteins, specifically the aromatic side chains, respectively. The ratios 
comparing these three wavelengths are used to assess purity. The 
260:280 ratio for RNA should be 2.0-2.2 to be confidant of a pure sample. 
A lower ratio however would indicate protein contamination. The 260:230 
ratio should also be very close to 2, and deviations lower than this would 
indicate the presence of organic solvents such as phenol or GITC. The 
perfect print out of a pure sample on the nanodrop would show a single 
sharp peak at 260nm and little else. 
Agarose gel electrophoresis is also very similar for DNA as it is RNA, but 
should appear as one distinct band at a size predicted by the number of 
bases you expect there to be.  
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3.2 Immunohistochemistry 
Immunohistochemistry involved the detection of protein expression 
through the use of fluorescent antibodies using tissue sections on 
microscope slides and western blot analysis. All tissue sections were of 
Mus musculus (mouse) tissue, donated from the Animal Facility at 
University of Waikato, New Zealand. The animals used were euthanised 
prior to our obtaining them for dissection, and so no Animal ethics 
approval was required from the University of Waikato. The mouse tissue 
section analysis was carried out in order to validate the GTX106683 
VMO1 antibody, new to our lab, sourced from GeneTex Inc., United States 
of America. The GTX106683 VMO1 antibody was compared to controls of 
β-actin, lysozyme, surfactin and a negative control with no primary 
antibody to demonstrate that both that the protocol is working and the ratio 
of signalling to noise. The western blot analysed the protein lysates of 
mouse lung, liver, kidney, and ear tissue, run alongside a standard of 
10mM bovine serum albumen (BSA) on a SDS-PAGE gel. In addition, 
sonicated solutions of commerical human cell lines THP-1 and BRCA1 
were also loaded, Once the protein samples was separated on the SDS-
PAGE gel, the protein was stained using Commassie blue or transferred to 
a membrane and VMO1 antibodies were applied and detected using 
chemiluminescence. 
3.2.1 General Materials and Methods 
Unless stated otherwise these statements hold true for methods outlined 
below. All microscope slides were sourced from Fronine. All 15mL falcon 
 
44 
tubes were sourced from All falcon tubes were Cellstar® branded supplied 
by Greiner Bio-one. Oxford labware Paraplast® paraffin was used in the 
Thermo Scientific™ HistoStar™ Embedding Workstation. SDS-PAGE gels 
were bought from Genscript, and we used the 12 well 4-20% Genscript 
express PAGE gels running in a Bio-Rad Laboratories Inc. Mini Protean® 
tetra system with MOPS buffer. Transfer of protein onto a nitrocellulose 
membrane for Western Blot was carried out using the eBlot® protein 
transfer system supplied by GenScript. Chemilumescence was detected 
using the Fujifilm LAS1000 with Intelligent Dark Box II and the 
accompanying LAS1000 lite V1.5 software. 
3.2.2 Slide Preperation 
In order for tissue sections to be retained on histological microscope slides 
during staining and washing steps, the slides being used needed to be 
coated with an adhesive compound such as gelatine.  
Before starting the process the 75x25mm single frosted Corning 
microscope slides (Corning Inc.) were first placed in 25 slide swing handle 
glass racks and soaked in hot tap water containing detergent for 1 hour 
before being rinsed for a further hour under running tap water to get rid of 
all detergent and soaked in distilled water for at least 15 minutes. They 
were then allowed to air dry. 
To prepare the gelatine solution, 1L of RNase free mQH2O (in case the 
slides were used for RNA work in the future) was brought to the boil, and 
then removed to the bench to cool. When the temperature reached 60°C, 
2g of porcine gelatine type A was added, and the solution allowed to cool 
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further. At 50°C, 0.1g potassium chrome III sulphate (KCr(III)SO4 was 
added, and the solution allowed to cool further again. When the 
temperature reached 35°C the solution was poured into glass tanks and 
the swing racks containing the cleaned, dried microscope slides were 
dipped into the gelatine mix for 1 minute, then dried on their side with 
frosted portion down for 5 minutes. The dip and dry process was repeated 
once for every rack. The microscope slides were then left in the swing 
racks to fully dry at 35°C. The coated slides were stored in the swing racks 
wrapped in tinfoil, with care taken not to touch the clear portion of the 
sides. 
3.2.3 Tissue Preparation for Paraffin Embedding 
Mouse tissue samples were dissected using sterilised instruments from 
freshly euthanised specimens and placed into 15mL falcon tubes 
containing 4% paraformaldehyde (made in 1xPBS) and left to fix overnight 
at 4°C on a shaking bed. The fixing ensures the preservation of cell 
morphology and tissue architecture 
Once fixed with 4% paraformaldehyde the tissue was then dehydrated 
through change of solutions outlined in Table 7 below, in preparation for 
embedding in paraffin. 
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Solution Temperature Time 
1xPBS 4°C 60 minutes 
0.85% NaCl 4°C 60 minutes 
50% ethanol Room temperature 30 minutes 
70% ethanol Room temperature 30 minutes 
70% ethanol Room temperature 30 minutes 
85% ethanol Room temperature 60 minutes 
95% ethanol Room temperature 60 minutes 
100% ethanol Room temperature 60 minutes 
100% ethanol* Room temperature 60 minutes 
Xylene Room temperature 30 minutes 
Xylene Room temperature 30 minutes 
Xylene Room temperature 30 minutes 
1:1 xylene:paraffin 60°C 45 minutes 
Triple filtered paraffin 60°C 20 minutes 
Triple filtered paraffin 60°C 20 minutes 
Triple filtered paraffin 60°C 20 minutes 
Table 7: Dehydration series for paraffin embedding. *Tissue can be stored at 4°C if 
there is not enough time to finish whole process. 
 
The tissue was then embedded in triple filtered paraffin using the 
embedding station. The embedded tissue can then be stored at room 
temperature until sectioned on a microtome. 
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3.2.4 Paraffin Section Treatment 
10µM sections were obtained and floated onto the pre-cleaned gelatine 
coated microscope slides using 0.2% ethanol in MQH2O. The sections 
were fixed to the slides by overnight dehydration on a 37°C hotplate. Table 
8 below outlines the protocol used to coat tissue sections with fluorescent 
antibodies. 
Solution Time 
Xylene  10 minutes 
Xylene 10 minutes 
100% ethanol 2 minutes 
100% ethanol 2 minutes 
95% ethanol 2 minutes 
70% ethanol 2 minutes 
50% ethanol 2 minutes 
30% ethanol 2 minutes 
1x PBS 5 minutes 
Antigen Revival Buffer (in glass jar, 
700W microwave) 
2 minutes 
Antigen Revival Buffer(in glass jar, 
700W microwave) 
2 minutes 
Cool slides to room temperature  
1x PBS 5 minutes 
1x PBS 5 minutes 
0.5% Triton X-100 30 minutes 
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1x PBS 5 minutes 
1x PBS 5 minutes 
0.9% H2O2 (in 1x PBS) 30 minutes 
1x PBS 5 minutes 
1x PBS 5 minutes 
1x PBST 5 minutes 
Block (5% Goat Serum) 30 minutes 
1:500 Primary Antibody in 5% goat 
serum. Used a PapPen. 
Overnight  in a humidity chamber 
at 4°C 
1x PBST 5 minutes 
1x PBST shaking 5 minutes 
1x PBST Shaking 5 minutes 
1:200 Anti Rabbit Ig Fluroscein in 1x 
PBS in dark 
30 minutes 
1x PBS 5 minutes 
1x PBS 5 minutes 
1x PBS 5 minutes 
Dry and mount coverslips  
Table 8: Antibody protocol for paraffin sections 
Slides were stored in the dark until photographed using a microscope 
(see 3.2.7), ideally the same day and no longer than a week post protocol 
to avoid any loss of fluorescent signal. 
3.2.5 Tissue Preparation for OCT 
As for paraffin sectioning, mouse tissue samples were dissected using 
sterilised instruments from freshly euthanised specimens and placed into a 
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6 well plate containing 4% paraformaldehyde (made in 1xPBS) and left to 
fix overnight at 4°C on a shaking bed. 
Once fixed with 4% paraformaldehyde the tissue was then dehydrated 
through change of solutions outlined in Table 9. 
Remove formaldehyde and wash tissue 
quickly with 1XPBS 
Not applicable 
wash tissue with 1XPBS 10 minutes 
wash tissue with 1XPBS 10 minutes 
wash tissue with 1XPBS 10 minutes 
Wash in 30% sucrose quickly n/a 
Wash in 30% sucrose 10 minutes 
Wash in 30% sucrose 10 minutes 
30% sucrose at  4°C rocking gently overnight 
Remove 1/2-1/3 of the sucrose and 
replace with OCT at  
4°C rocking gently for 1 hour 
Fill one cryomold container with OCT and 
place one tissue specimen in using sterile 
tweezers. Take care to get as little 
sucrose/OCT mix into the OCT as 
possible. 
Not applicable 
Table 9: Dehydration protocol for OCT 
Embedded tissue was stored at -80°C until sectioned using a Leica DMR 
Microscope with a Nikon Digital Camera attached. 
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3.2.6  OCT Section Treatment  
Sections were prepared (10μm) using the Leica CM1850 UV cryostat 
(Leica Biosystems) and collected onto gelatine coated pre-cleaned 
microscope slides (kindly donated by Patrick Wightman). Slides had been 
stored in a slide box at -20°C and thawed overnight before continuing with 
the antibody protocol. Table 10 below outlines the antibody protocol used 
with these OCT slides. 
Precooled -20 C acetone (in 
fumehood) 
10 minutes 
1x PBS (pH 7-7.5) 5 minutes 
1x PBS 5 minutes 
1x PBS 5 minutes 
0.5 Triton X 30 minutes 
1x PBS 5 minutes 
1x PBS 5 minutes 
1x PBS 5 minutes 
0.9% H202 (in 1x PBS) 30 minutes 
1x PBS 5 minutes 
1x PBS 5 minutes 
1x PBST 5 minutes 
Block with blocking buffer 30 minutes 
Wipe excess fluid with tissue; encircle 
tissue with pap pen and let dry 
2 minutes 
1x PBS 5 minutes 
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1:500 primary antibody in blocking 
buffer  
Overnight  in a humidity chamber 
at 4°C 
1x PBS 15 minutes 
1x PBS shaking (orbital shaker speed 
4) 
15 minutes 
1x PBST shaking 15 minutes 
1:200 FITC conjugated goat andti-
rabbit IgG (H+L) polyclonal antibody 
(in 1x PBS) 
30 minutes 
1x PBS 15 minutes 
1x PBS 15 minutes 
1x PBST 60 minutes 
1x PBST 60 minutes 
Dry in dark 1 hour 
Mount using fluroshield with DAPI  
Dry in dark Overnight 
Photograph and store  
Table 10: Antibody protocol for OCT 
Slides were stored in the dark until photographed using a Leica DMR 
Microscope with a Nikon Digital Camera attached microscope, ideally the 
same day and no longer than a week post protocol to avoid any loss of 
fluorescent signal. 
3.2.7 Microscopy 
Immunohistochemistry stained slides were visualised on a Leica DMR 
Microscope with a Nikon Digital Camera attached. The FITC secondary 
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antibody was conjugated to the VMO1, lysozyme, surfactin and β-actin 
primary antibodies and was visualised with UV light and a 460-490nm cube 
filter.  
3.2.8 Bradford Assay 
The Bradford assay was used to estimate the protein concentration of 
samples extracted from mouse tissue and human cells prior to the western 
blot analysis. BSA standard dilutions were prepared from a 10mM stock to 
final concentrations of 0mM, 0.1mM, 0.25mM, 0.5mM, 1mM, 2mM, 4mM, 
6mM, 8mM, and 10mM in mQH2O. The Bradford standard can be found in 
Appendix 1. Protein lysates for the mouse ear, kidney, liver and lung were 
thawed from -20°Cstocks supplied by the Department of Biological 
Sciences, University of Waikato. Cell samples were prepared by adding 
200µL of PhosSTOP (Roche) to cell pellets to prevent protein degradation, 
then sonicating them with three bursts of 30seconds. 1µL of samples and 
standards were then pipetted into a 96well plate and 100µL of Bradford’s 
reagent added. The plate was then stored in the dark for 5minutes before 
analysed on a Thermo Fisher Scientific Inc. Multiskan™ GO Microplate 
Spectrophotometer and its accompanying software to gain an indication of 
the protein concentration in each sample. 
3.2.9 Western Blot analysis 
Protein samples were aliquoted into tubes containing Laemmli buffer 
(Appendix 1). This buffer contains 2-mercaptoethanol which reduces the 
intra and inter-molecular disulfide bonds, SDS detergent which denatures 
the proteins and subunits and gives each an overall negative charge so 
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that each will separate based on size, bromophenol blue serves as a dye 
front that runs ahead of the proteins so you can see the sample during 
loading and the glycerol increases the density of the sample so that it will 
layer in the sample well. To ensure equal sample loading, 10µL of 
Laemmli buffer was mixed wtih 20µL protein sample for the mouse ear, 
and human cell lines, 20µL buffer to 10µL protein sample for the other 
mouse tissues, and 45µL buffer to 5µl of BSA 10mM standard (only 10µL 
was loaded). These were then run on a 12% Genscript PAGE gel as 
outlined above, using MOPS buffer and running at 200mV for 
approximately half an hour. The gel was then rinsed with distilled water 
before being transferred to the eBlot® protein transfer system, which was 
set up according to manufacturer’s instructions. The eBlot® machine was 
then run for 7 minutes, to transfer across all protein to the provided 
nitrocellulose membrane. 
Once the protein was transferred to the membrane, the membrane was 
carefully transferred to a container and washed three times with TBS-T for 
15minutes per wash, then once for 15minutes with TBS before being 
washed with 5% blocking buffer. The membrane was left in the blocking 
buffer for 1 hour to prevent the nonspecific binding of the antibodies before 
being washed three times with TBS-T for 15minutes per wash, then once 
for 15minutes. 1:1000 VMO1 antibody was then applied to the membrane 
and left at 4°C overnight. The membrane was then washed again before 
application of the secondary 1:200 FITC conjugated goat andti-rabbit IgG 
(H+L) polyclonal antibody. This was left to incubate for an hour before 
draining and developing the membrane. 
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The chemilumesnce was developed using Thermo Scientific™ 
SuperSignal™ West Dura Substrate mixed 1:1 as per manufacturer’s 
instructions, before being analysed using the Fujifilm LAS1000 and its 
accompanying software. 
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4.1 VMO1 RNA 
4.1.1 RNA Extraction 
RNA was extracted from A549 (lung carcinoma), THP1 
(monocytic cell line), and BRCA1 (breast cancer) cell 
lines and visualised on a 1% native agarose gel to 
determine quality as shown in Figure 4. The Two 
expected rRNA bands were observed, indicating the 
integrity of RNA was high. Therefore, the RNA 
extracted was used as a template for cDNA synthesis. 
4.1.2 Primer Design 
Primers were designed using NCBI Primer-BLAST based on the transcript 
variant 1 of human VMO1 mRNA (NM_182566.2) sourced from the NCBI 
Nucleotide database and designed to be exon spanning to be able to 
distinguish between cDNA that has been made from the extracted mRNA 
(see Figure 5) and the VMO1 gene from genomic DNA. Three primers 
were designed, two forward (F) and one reverse (R) (Table 4), that hit 
nothing else except human VMO1 when using NCBI BLAST analysis .  
4 Results  
Figure 4: rRNA 
bands extracted 
from BRCA1 and 
A549 cell lines 
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4.1.3 PCR Amplification of VMO1 
PCR amplification was carried out on the cDNA of three samples that were 
synthesised from  RNA extracted from A549, THP1 and BRCA1 cell lines. 
These were run against a house keeping gene of GAPDH for which the 
primers have been previously published [24]. Figure 6 shows the 
amplification of the VMO1 transcripts from these tissues, with A549 in lane 
three of (1) being the only cell line to positively amplify VMO1 of the three. 
In addition, results show suggest the identification of at least three of the 
four transcript variants. The remaining two cell lines did not amplify VMO1, 
and were run alongside the housekeeping gene GAPDH to show that the 
failure of amplification was due to there being no transcript present rather 
than because there was an issue with the quality of cDNA template. All 
PCR was free of contamination as shown by the clear lanes for the 
negative controls. 
Figure 5: Exon spanning primer design. Diagram showing where each primer hits against all 
four transcripts of VMO1. 
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Figure 6: PCR amplification of VMO1. (1) 1% Agarose Gel Electrophoresis from left to right- 1KB 
ladder (1), THP1 cDNA with VMO1 primer set one (2), A549 cDNA with VMO1 primer set one 
(3), negative control (4). (2) ) 1% Agarose Gel Electrophoresis from left to right- 1KB ladder (1), 
BRCA1 cDNA with VMO1 primer set one (2), BRCA1 cDNA with GAPDH primer set (3), negative 
control (4), THP1 cDNA with VMO1 primer set one (5), THP1 cDNA with GAPDH primer set(6), 
negative control. 
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4.2 Plasmid  
4.2.1 Nanodrop 
 
4.2.2 Restriction Digest of Transformed Plasmid 
Extracted plasmid was digested using EcoR1 and Xba1. Two different 
extraction methods were used to compare efficiency and all samples were 
run on a 2% gel with undigested and digested samples side by side. The 
Zyppy™ kit was far superior in its quality even though the nanodrop 
showed it had lower concentrations of DNA. The colony that gave rise to 
sample five was selected to be grown overnight in 6mL of LB at 250rpm 
and frozen into glycerol stocks for future expression work. 
Figure 7: Restriction digest of VMO1 plasmid. Top shows 
original extraction protocol. Low concentration of extracted 
DNA. Bottom shows DNA extracted from kit. All samples 
were loaded in pairs of undigested then digested. Run on a 
2% agarose gel against a 100bp ladder. 
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Figure 8: Histological cochlea cross section. Shows main structures of the 
cochlea 
Sample five was sent for sequencing post cleanup, and was sequenced 
using the M13F and M13R primers supplied with the vector. The 
sequences were edited using Geneious version 7.0.06. The sequences 
were aligned using NCBI BLAST with VMO1 transcript variant 2 with 100% 
sequence homology indicating that VMO1 is indeed ligated into our clone. 
Sequences are shown in Appendix four. 
4.3 Immunohistological Analysis  
4.3.1 Tissue Section Analysis 
Analysis of P5 mouse tissue sections was carried out on both paraffin and 
OCT sections. The mouse ear (Figure 8) is important for the validation of 
VMO1 as it contains the Reissner’s membrane which is the only area that 
VMO1 is known to be expressed in the mouse, and we could only obtain 
sections through the use of OCT as there were issues with the 
decalcification of the head samples used for paraffin sectioning. 
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Fluorescent microscopy was used to visualise antibody activity with VMO1. 
Signal (green) was detected in Reissner’s membrane and within the inner 
ear. For the mouse inner ear, we used lysozyme as a house keeping 
antibody, which showed some activity, and then with no primary antibody, 
to show background levels of fluorescence. This was then compared to 
the lung tissues to determine that the VMO1 antibody does not show any 
nonspecific binding. In addition, this was compared to the house keeping 
surfactin antibody, which is used as a marker of type 2 cells in the lung. 
Brighter green spots on panel 5 in Figure 9 were observed which indicated 
type 2 cells. This was again compared to a section with no primary 
antibody to show background noise, which would appear to be the source 
of any fluorescence seen in panel 4 (Figure 9) showing VMO1 antibody 
binding in the lung. 
  
Figure 9: Fluorescent antibody analysis. Top row shows mouse inner ear sections with 1) 
treated with VMO1 1:500, 2) treated with lysozyme 1:500, and 3) treated with no primary 
antibody. Bottom row shows mouse lung sections with 4) treated with VMO1 1:500, 5) treated 
with surfactin 1:1000, and 6) with no primary antibody.  
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4.3.2 Western Blot 
Western blot analysis showed non-specific binding of VMO1 protein, with 
multiple banding in all lanes, as well as being detected in other tissues 
besides the ear, even though there is data to indicate this should not be 
the case. The protein marker ladder was overlaid from fluorescent imaging, 
and the membrane was left for an exposure of 80seconds for the 
chemiluminesce to be captured.  
No protein was shown in the BSA lane or the THP1 lane, although there is 
a faint band in the BRCA1 lane, which contradicts the findings of the PCR 
analysis of mRNA extracts. The absence of protein was not because of 
lack of protein, but rather that it did not bind to the VMO1 antibody. This 
was checked by staining the membrane with PonceauS stain for an hour. 
 
 
Figure 10: Western blot of tissues. Ladder from fluorescent detection 
overlaid using Microsoft paint. 
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5.1 VMO1 expression 
5.2 VMO1 expression 
VMO1 has an unknown expression profile in human tissues, and the 
research aim of this thesis was to provide some insight as to where it is or 
is not expressed. The EST data generated from Ensembl indicated a 
number of tissues where we would expect to find VMO1 expression, 
although due to set backs and cell line availability we were only able to 
analyse three cell lines. 
Firstly, hela cells were cultured using aseptic cell techniques to 100% 
confluency and then the RNA was extracted. However, our RNA extraction 
protocol was the first set back, having tried one method which using the 
maufacturer’s instructions for Trizol® Reagent supplied by Life 
Technologies™. This technique yielded low yields of poor quality RNA 
determined through agarose gel electrophoresis and nanodrop readings, 
which were unable to continue downstream to cDNA synthesis and PCR. 
This could be due to the RNA pellet no being fully solubilised, or that the 
cells remained adhered to the plates. Possibly there was not enough Trizol 
reagent added, or perhaps the sample was not homogenised enough. 
Therefore, an alternative method was sourced. Using GITC yielded the 
observation of two ribosomal bands on the agarose gel, indicating the 
5 Discussion and Future Directions 
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RNA was of high integrity. Therefore, the RNA could then be used for the 
downstream applications. 
PCR conditions were another hurdle to the determination of VMO1 
expression. Initially, running the PCR conditions with annealing at 55°C 
ended with no amplification, indicating that the primers were not working.. 
New reactants were used to no avail, and a gradient of Mg+ concentrations 
ranging from 1.5-2.5 mM also had no effect. Gradient PCR was then used 
initially between 50°C and 55°C to no effect, and then over a gradient of 
50°C to 60°C, which finally yielded a result.  
Analysis of the PCR results from cDNA synthesised from mRNA 
transcripts from the three different human cell types showed that there 
was VMO1 expression in the lung (A549 cells) but not in the breast 
(BRCA1 line SUM149PT carrying the 2288delT mutation) or white blood 
cells (THP1). This result is in accordance to the EST data which lists the 
lung as a potential area for the expression, and not the white blood cells, 
although there is a discrepancy in that the PCR does not show any 
expression of VMO1 in the BRCA1 cell line, although there is EST data 
available for VMO1. Interestingly, VMO1 and BRCA1 are both expressed 
on chromosome 17. In addition, we have used only one of the 43 BRCA1 
cell lines available on the commercial market. Possibly, our designed 
primers did not target a VMO1 isoform in the breast.  
5.3 Development of Recombinant VMO1 DNA  
Creating a plasmid construct containing VMO1 was the other primary 
objective of this research in order to be used for further studies of the 
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protein. This was ultimately successful with a transformed E. coli glycerol 
stock being frozen and stored at -80°C. 
Initially, the vector pBluescript (2958bp) was transformed into 
electrocompetant cells to proliferate before being extracted using , 
digested with EcoR1 and t-tailed for ligation. T-tailing is required to insert 
mRNA transcripts as Taq DNA polymerase adds a poly-adanine tail to the 
3’ of all transcripts, and this then base pairs with the many thymine 
restudies added during t-tailing. pBluescript is a commercial vector that 
offers extensive multiple cloning site with 21 unique restriction enzyme 
recognition sites. 
The DNA extraction method was carried out on approximately 1mL of 
culture and used TENS (Tris-Cl, EDTA, NaCl, SDS) buffer which yielded 
low quantities of DNA which were inadequate for further downstream use. 
The low yield could be due to having too many steps where DNA could be 
lost along the way, or that pH of solutions was incorrect, poor culturing 
conditions (although cultures were not used unless the media was cloudy 
which would indicate growth) or that the cells were insufficiently lysed. The 
nanodrop readings were initially very high, around 1000ng/µL, but when 
run on a agarose gel there was little plasmid DNA observed but a high 
density RNA cloud, which was subsequently removed by the addition of 
RNase A to the protocol (results not shown).  
To improve the cloning methdology, a new commerical plasmid was 
obtained; pLUG vector, which required no preparation before ligation. 
However, the application of this vector upon ligation with the purified 
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VMO1 lung DNA yielded no colonies on the agar plate when used in 
conjunction with electroporation. Following review over the manufacturers 
guidelines, colonies developed when ligated samples were transfomred 
using chemically competent cells (E. clonii) rather than electrocompetent 
bacterial cells.  
A new DNA extraction protocol (included in section 3.1.11) was used to 
extract the plasmid from these cells for downstream use, and proved 
successful as bands of the expected size were obtained and the nanodrop 
reading was more accurate to what was seen on the gel. The pLUG vector 
with the VMO1 insert was also used in conjunction with the mix & go kit, 
resulting in the highest transformation efficiency of the three 
transformation protocols used in this study. The Zyppy™ Plasmid Miniprep 
Kit extraction was also compared to the alkaline lysis method used 
previously. The Zyppy™ kit yielded lower concentrations of plasmid DNA 
but of a much higher quality and is much quicker. 
The final extracted product was verified as VMO1 through colony PCR and 
restriction digest using XX and XX. In addition, the DNA was sent to 
Waikato DNA Sequencing Facility for sequencing using the M13 
sequencing primers. Following data analysis,  
 
Glycerol stocks were also made and stored for future experimentation. 
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5.4 Antibody Validation 
The validation of the VMO1 antibody was a secondary objective of the 
work of this thesis. VMO1 expression is known to be limited to the 
Reissner’s membrane in mice [1] and so should be the only structure to 
show activity with the antibody.  
Using OCT sections we were able to verify this, with the Reissner’s 
membrane and nearby structures showing a stronger green signal than 
any background. The fact that nearby structures were also showing a 
positive reaction to the VMO1 antibody would suggest that VMO1 is a 
secreted protein. It was also not picked up in the lung sections, which 
shows that there is little non-specific binding, if any, from this antibody 
although the surfactin antibody that served as a positive control worked 
well, and the type II cells were observed as expected. 
It would have been ideal if we could have validated the antibody using 
paraffin sections alongside the OCT sections; however we had no slides of 
the mouse ear to verify on. This is due to the decalcification protocol not 
being stringent enough, which left too much bone intact. This meant that 
any sections would tear on the blade, no matter how much the section 
thickness was increased. There was no opportunity to gain another mouse 
head to test another decalcification method on within the time frame of this 
thesis, and without the ear slides there could be no positive validation of 
this antibody. 
On the western blot analysis, the antibody seemed to have significant 
nonspecific binding, as it was detected not only in the mouse ear, but also 
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the lung, liver and kidney. The lung may express VMO1 in low levels, that 
could have been missed on the histological slides as not all of the lung 
was sectioned, but the whole lung lysate was used on the western. There 
was also a band at the right size in the BRCA1 lane. Being a very faint 
band this could be a false positive, due to the other lanes all having VMO1 
bands even though there should be no VMO1 present in those tissues, or 
else the western was able to detect low levels of VMO1 in the BRCA1 
cells where the PCR could not. However cancerous cell lines may not be 
the best model to represent normal tissue as there are a number of 
mutations inherent within the cancerous genome. 
I would worry then that the results seen in the studies of camel tear film 
[16,17] may not be entirely accurate as this is the same antibody used in 
their papers. Otherwise there may be a problem with our antibody perhaps 
due to shipping or production conditions. The antibody we obtained was 
immediately aliquoted into 5µL aliquots to minimise the need to freeze and 
thaw the antibody more than needed and stored at -20°C. 
The non-specific binding seen could be at least partially due to the 
possibility that the VMO1 protein could have multiple modified forms in 
vivo such as acetylation, methylation, myristylation, phosphorylation, 
glycosylation etc. that make it run as multiple bands. The use of an agent 
to dephosphorylate, de-glycosylate, and otherwise counteract post 
transcriptional modification of the protein could be recommended in the 
future to bring the protein to the correct size. Aother reason for the multiple 
banding pattern is that VMO1 may bind tighly to other proteins to form a 
complex, which could be counteracted by boiling the  sample for longer. 
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Changing the blocking buffer from milk poweder to the blocking buffer we 
used for the molecular probes on the slides might also help to avoid non-
specific binding, as we know that there was none when looking at VMO1 
antibody on the slides.  
In conclusion, further research is required on the validation of the VMO1 
antibody. An investigation into more stringent decalcification methods to 
improve the integrity of the paraffin ear sections would be beneficial. We 
used postnatal day (P5) five ear tissue for the ease of dissection and 
sectioning. It would be desirable to use adult ears (at least P28) and organ 
tissue at P5 for the immunohistochemical comparisons.  
5.5 Future Directions 
There are two main directions for this thesis to continue in regards to 
investigating the function of VMO1. Firstly, sampling a wider variety of 
human cell lines to extract RNA and test for expresion of VMO1. In 
particular, obtaining alternative BRCA1 cell lines and human biopsy breast 
tissue samples would be useful to clarify VMO1 expression in this tissue.  
Secondly, once a VMO1 antibody has been validated to recognise 22 kDa 
protein on the western blot, you could use this antibody to determine 
function of VMO1 by investigating the protein-protein interactions. This 
could be achieved by using the digested the VMO1 insert and cloning into 
a protein expression vector using define restriction enzymes or resigning 
primers with restriction enzymes to amplfy of lung cDNA. By knowing what 
VMO1 interacts with, a pathway could then be inferred and a potential 
function elucidated. This could then be combined with enzymatic assays 
 
69 
using a range of saccharide substrates, as it is thought that the binding 
domain is similar to other proteins that do work on saccharides [2]. 
Overexpression, and mutation studies could also be conducted to analyse 
whether the VMO1 protein is toxic to the cell, or if any change occurs in 
the natural function of the cell.  
Finally, no animal model has been published for VMO1 to date. However, 
mutant embryonic stem cells are available purchase for the development 
of a VMO1 knockout mouse (https://www.mousephenotype.org). It would 
be interesting to determine if these animals had a hearing loss phenotype. 
5.6 Conclusion 
RNA was extracted from three human cell lines (A549, THP1 and BRCA1) 
and converted to cDNA using reverse transcriptase. PCR primers were 
designed to amplify the VMO1 coding regions that covered the open 
reading fram (exons 1-3) to ligated and clone into pLUG vector. Following 
PCR optimisation, an annealing temperature of 55°C was identified and 
resulted in the amplification of cDNA synthesised from lung (A549). The 
PCR product was purified and ligated into the pLUG vector, transformed 
using XXX. Following colony PCR and restriction digestion analysis, a 
positive clone was sent to DNA sequencing. Analysis of the consensus 
sequence confirmed that VMO1 was amplified from lung cDNA. The next 
step is to use this data to clone into a protein expression vector. This will 
aid future studies on VMO1. 
The immunohistochemistry data suggests that the VMO1 protein is a 
secreted protein since signal was detected in the P5 mouse inner ear and 
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mouse adult lung. However, multiple bands were observed in the western 
blot. Futher investigation is required to validate the VMO1 antibody to 
demonstrate that it is indeed specific to recognising its target epitope.  
With so little known about the VMO1 protein, especially outside of the 
chicken, there are a myriad of possibilities to be examined and many 
routes to be discovered that lie outside the bounds of this thesis. For 
example, the crystal structure of mouse and human VMO1 needs to be 
determined by X-ray crystallography, and compared to both the chicken 
VMO1 structure and other human and mouse proteins that could be 
homologous. Protein partners are another crucial step in elucidation, if not 
a function, then the pathway in which it is involved. Considering the 
localisation of VMO1 in the mouse inner ear, a, VMO1 knockout mice 
could be developed to discover a potential hearing loss phenotype, and 
with human ethics approval human samples could be taken and 
sequenced to see if there is any single nucleotide polumorphisms (SNP’s) 
involved that could lead to a hearing loss phenotype.  
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6X Agarose gel loading buffer 
 3mL Glycerol 
 25mg Bromophenol Blue 
 20μl Xylene Cyanole 
 Make up to 10mL with sterile mQH2O 
Antigen revival buffer – sodium citrate buffer 
 1.47g Tri-sodium citrate (dehydrate) 
 Make up to 500mL with mQH2O and autoclave 
 250μl Tween 20 
Blocking solution for Immunohistochemistry 
 200µL Goat serum 
 1mL 1X PBS 
Blocking solution for Western Blot 
 5g Low fat milk powder 
 50mL 1X TBS-T 
Bradford Reagent 
 1part Dye reagent concentrate 
 1 part mQH2O 
Appendix One: Solutions and Buffers 
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 Filter through a Whatman #1 filter paper to remove particulates 
10X cOmplete Protease Inhibitor Cocktail 
 1mL 1X PBS 
 1 cOmplete Protease Inhibitor Cocktail Tablet (Roche) 
0.5M EDTA pH 8.0 
 93.05g EDTA 
 Make up to 500mL with mQH2O and autoclave 
2X Freezing medium 
 6.30g K2HPO4 
 0.45g Sodium citrate 
 0.09g MgSO4.7H2O 
 1.80g (NH4)2SO4 
 44.00mL Glycerol 
 Make up to 500mL with mQH2O and autoclave 
IPTG – Isopropylthiogalactoside 
 200mg IPTG 
 1mL dH2O 
2x Laemmli Dye 
 4mL 10% SDS 
 2mL Glycerol 
 1.2mL 1M Tris pH6.8 
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 200µL Bromophenol Blue 
 2.6mL H2O 
 Just before use, take 475µL of 2x dye and add 25µL β-
mercaptoethanol 
LB broth – Luria Base broth pH 7.0 
 10g Bactotryptone 
 5g Bacto yeast extract 
 10g NaCl 
 Make up to 1L with mQH2O and autoclave 
LB plates – Luria base agar plates 
 1L LB broth 
 15g Bactoagar 
 Autoclave and add antibiotics at 50°C before pouring 
1x MOPS running buffer 
 6.06g Tris base 
 10.46g MOPS 
 1g SDS 
 0.3g EDTA 
 To 1L with deionised H2O 
1X PBS – phosphate buffered saline pH 7-7.4 
 8g NaCl 
 0.25g KCl 
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 0.2g KH2PO4 
 1.15g Na2HPO4 
 Make up to 1L with mQH2O. 
4% PFA - paraformaldehyde 
 4.0g PFA 
 10.0μl 10M NaOH 
 Make up to 50mL with mQH2O and heat in 65°C water bath to 
dissolve 
1X PBS-T – phosphate buffered saline + Tween-20 pH 7-7.4 
 1L PBS 
 0.5mL Tween-20. 
10X PhosSTOP Phosphatase Inhibitor Cocktail 
 1mL 1X PBS 
 1 PhosSTOP Phosphatase Inhibitor Cocktail Tablet (Roche) 
Ponceau S stain 
 0.1g Ponceau S 
 0.1g Acetic acid 
 Make up to 1L with mQH2O 
Protein lysis buffer 
 2.5mL 1M Tris 
 1.9mL 4M NaCl 
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 200μl 0.5M EDTA 
 250μl Triton-X 100 
 0.5mL 1X PhosSTOP Phosphatase Inhibitor Cocktail 
 0.5mL 1X cOmplete Protease Inhibitor Cocktail 
 Make up to 50mL with sterile mQH2O 
10% SDS 
 100g SDS in 800mL sterile mQH2O  
 Up to 1L with sterile mQH2O 
Solution I (Lysis buffer I) - 50mM Glucose, 10mM EDTA, 25mM Tris pH8 
 0.9g Glucose. 
 2mL 0.5 EDTA. 
 2.5mL 1M Tris pH8. 
 Make up to 100 mL with H2O. 
 Autoclave and store at room temperature. 
Solution II (Lysis buffer II) - 0.2N NaOH, 1% SDS.  
Prepare fresh for each extraction. 
 0.2mL 10M NaOH. 
 1mL 10% SDS. 
 Make up to 10mLs. 
Solution III (Lysis buffer III) - 3M KOAc pH6 
 60mL 5M potassium acetate (49.07g potassium acetate in 100mL 
H2O.) 
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 11.5mL glacial acetate. 
 28.5mL H2O. 
50X TAE - Tris-acetate EDTA buffer 
 242g Tris base dissolved in 800 mL mQH2O 
 57.1mL Glacial acetic acid 
 100mL 0.5M EDTA (pH 8.0) 
 Make up to 1L with mQH2O 
1X TAE running buffer 
 20mL 50X TAE 
 980mL mQH2O 
 0.1% DEPC treated water - diethyl pyrocarbonate 
 2mL DEPC 
 Make up with 2L mQH2O, mix overnight using a magnetic stirrer, 
then 
1X TBS - Tris buffered saline 
 50mL 1M Tris 
 30mL 5M Sodium chloride 
 Make up to 1L with mQH2O and autoclave 
1X TBS-T - Tris buffered saline + Tween-20 
 999mL TBS 
 1mL Tween-20 
TE buffer – Tris EDTA pH 8.0 
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 10mL 1X Tris-HCl 
 2mL 0.5M EDTA 
 0.9% H2O2 
 16.7mL H2O2 
 Make up to 500mL with 1X PBS 
1M Tris HCL pH 8.0 
 500mL H2O 
 60.5g Tris 
 Autoclave 
XGAL - 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
 20mg Xgal 
 1mL Dimethyl formamide 
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Appendix Two: Plasmid Vectors 
Figure 11: map of pLUG®-multi TA cloning vector 
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Line one= transcript one (NM_182566.2). Line two= transcript two (NM_001144939.1). Line three= transcript three (NM_001144940.1). Line 
four= transcript four (NM_001144941.1). 
>Exon one 
AGGCCCTTCCGCAATCGGAGCCCTCACAGAGGCCAAACTGATATAAATCTGCTTAGGAGGCCTGATTCACAGACGCTACAGGATGGAGCGGGGCGCAGGAGCCAAGCTGCTGCCGC 
AGGCCCTTCCGCAATCGGAGCCCTCACAGAGGCCAAACTGATATAAATCTGCTTAGGAGGCCTGATTCACAGACGCTACAGGATGGAGCGGGGCGCAGGAGCCAAGCTGCTGCCGC
AGGCCCTTCCGCAATCGGAGCCCTCACAGAGGCCAAACTGATATAAATCTGCTTAGGAGGCCTGATTCACAGACGCTACAGGATGGAGCGGGGCGCAGGAGCCAAGCTGCTGCCGC
AGGCCCTTCCGCAATCGGAGCCCTCACAGAGGCCAAACTGATATAAATCTGCTTAGGAGGCCTGATTCACAGACGCTACAGGATGGAGCGGGGCGCAGGAGCCAAGCTGCTGCCGC
TGCTGCTGCTTCTGCGGGCGACTGGTTTCACATGTGCACAGACAGATGGCCGGAACGGCTACACGGCGGTCATCGAAGTGACCAGCGGGGGTCCCTGGGGCGACTGGGCCTGGCCT
TGCTGCTGCTTCTGCGGGCGACTGGTTTCACATGTGCACAGACAGATGGCCGGAACGGCTACACGGCGGTCATCGAAGTGACCAGCGGGGGTCCCTGGGGCGACTGGGCCTGGCCT
TGCTGCTGCTTCTGCGGGCGACTGGTTTCACATGTGCACAGACAGATGGCCGGAACGGCTACACGGCGGTCATCGAAGTGACCAGCGGGGGTCCCTGGGGCGACTGGGCCTGGCCT
TGCTGCTGCTTCTGCGGGCGACTGGTTTCACATGTGCACAGACAGATGGCCGGAACGGCTACACGGCGGTCATCGAAGTGACCAGCGGGGGTCCCTGGGGCGACTGGGCCTGGCCT
GAGATGTGTCCCGATGGATTCTTCGCCAGCGGGTTCTCGCTCAAG 
GAGATGTGTCCCGATGGATTCTTCGCCAGCGGGTTCTCGCTCAAG 
GAGATGTGTCCCGATGGATTCTTCGCCAGCGGGTTCTCGCTCAAG 
GAGATGTGTCCCGATGGATTCTTCGCCAGCGGGTTCTCGCTCAAG 
>Exon two 
GTGGAGCCTCCCCAAGGCATTCCTGGCGACGACACTGCACTGAATGGGATCAGGCTGCACTGCGCGCGCGGGAACGTCCTAGGCAATACGCACGTGGTAGAGTCCCAGTCTGGAA- 
GTGGAGCCTCCCCAAGGCATTCCTGGCGACGACACTGCACTGAATGGGATCAGGCTGCACTGCGCGCGCGGGAACGTCCTAGGCAATACGCACGTGGTAGAGTCCCAGTCTGGAAG 
GTGGAGCCTCCCCAAGGCATTCCTGGCGACGACACTGCACTGAATGGGATCAGGCTGCACTGCGCGCGCGGGAACGTCCTAGGCAATACGCACGTG-------------------- 
-------------------------------------------------------------------------------------------------------------------- 
----------------------------------- 
GTGGGGCGCAGGGGTCGAGGATCCCTTGGGGTGAT 
----------------------------------- 
----------------------------------- 
>Exon three 
GCTGGGGCGAATGGAGTGAGCCGCTGTGGTGTCGCGGCGGCGCCTACCTAGTGGCTTTCTCGCTTCGCGTGGAGGCACCCACGACCCTCGGTGACAACACAGCAGCGAACAACGTG 
Appendix Three: VMO1 mRNA Alignments 
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GCTGGGGCGAATGGAGTGAGCCGCTGTGGTGTCGCGGCGGCGCCTACCTAGTGGCTTTCTCGCTTCGCGTGGAGGCACCCACGACCCTCGGTGACAACACAGCAGCGAACAACGTG
-CTGGGGCGAATGGAGTGAGCCGCTGTGGTGTCGCGGCGGCGCCTACCTAGTGGCTTTCTCGCTTCGCGTGGAGGCACCCACGACCCTCGGTGACAACACAGCAGCGAACAACGTG 
-CTGGGGCGAATGGAGTGAGCCGCTGTGGTGTCGCGGCGGCGCCTACCTAGTGGCTTTCTCGCTTCGCGTGGAGGCACCCACGACCCTCGGTGACAACACAGCAGCGAACAACGTG 
CGCTTCCGCTGTTCAGACGGCGAGGAACTGCAGGGGCCTGGGCTGAGCTGGGGAGACTTTGGAGACTGGAGTGACCATTGCCCCAAGGGCGCGTGCGGCCTGCAGACCAAGATCCA
CGCTTCCGCTGTTCAGACGGCGAGGAACTGCAGGGGCCTGGGCTGAGCTGGGGAGACTTTGGAGACTGGAGTGACCATTGCCCCAAGGGCGCGTGCGGCCTGCAGACCAAGATCCA
CGCTTCCGCTGTTCAGACGGCGAGGAACTGCAGGGGCCTGGGCTGAGCTGGGGAGACTTTGGAGACTGGAGTGACCATTGCCCCAAGGGCGCGTGCGGCCTGCAGACCAAGATCCA
CGCTTCCGCTGTTCAGACGGCGAGGAACTGCAGGGGCCTGGGCTGAGCTGGGGAGACTTTGGAGACTGGAGTGACCATTGCCCCAAGGGCGCGTGCGGCCTGCAGACCAAGATCCA
GGGACCTAGAGGCCTCGGCGATGACACTGCGCTGAACGACGCGCGCTTATTCTGCTGCCGCAGTTGAACGGCGCCGCCGCCGCCGCTCTCTCCCGGGCCAGGAGGCTAGTCCCACC
GGGACCTAGAGGCCTCGGCGATGACACTGCGCTGAACGACGCGCGCTTATTCTGCTGCCGCAGTTGAACGGCGCCGCCGCCGCCGCTCTCTCCCGGGCCAGGAGGCTAGTCCCACC
GGGACCTAGAGGCCTCGGCGATGACACTGCGCTGAACGACGCGCGCTTATTCTGCTGCCGCAGTTGAACGGCGCCGCCGCCGCCGCTCTCTCCCGGGCCAGGAGGCTAGTCCCACC
GGGACCTAGAGGCCTCGGCGATGACACTGCGCTGAACGACGCGCGCTTATTCTGCTGCCGCAGTTGAACGGCGCCGCCGCCGCCGCTCTCTCCCGGGCCAGGAGGCTAGTCCCACC
TCTTGCTATTAAAGCTTCTCTGAGTTGAAAAAAAAAAAAAAAAAA 
TCTTGCTATTAAAGCTTCTCTGAGTTGAAAAAAAAAAAAAAAAAA 
TCTTGCTATTAAAGCTTCTCTGAGTTGAAAAAAAAAAAAAAAAAA 
TCTTGCTATTAAAGCTTCTCTGAGTTGAAAAAAAAAAAAAAAAAA
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>M13F primer (supplied with plasmid kit) 
 
Figure 12: Restriciton digest sequence with M13F primer edited on Geneious 7.0.06 
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>M13R primer (supplied with plasmid kit) 
 
Figure 13: Restriciton digest sequence with M13F primer edited on Geneious 7.0.06 
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C2 Laboratories, Biological Sciences Department, UoW 
Containment Manual, Version 6.5 issued on 17-02-12 
Form for Lab records of New Organisms Register of GMOs 
Developed in Facility Number 759 
HSNO ACT APPROVAL No. APP201152     UOW Appl. No: GMD101146 
PROJECT: Characterisation of VMO1 in Human Tissues 
P.C.LEVEL: 1                                                  Additional Controls: 
Researcher: Hannah Crossan 
*Project Leader/Supervisor: Dr. Linda Peters 
Host Species and Strain: E. coli strain DH5
Vector: pLUG                                               Insert DNA: Human Vmo1 
Species of donor of nucleic acids: Mus musculus 
Note: all records must be dated and initialled. Continue on a new page if necessary. 
DATE NAME OF 
GMO 
Assign a code and 
number 
STORAGE 
DETAILS 
Specify fridge or freezer 
TRANSFER 
DETAILS 
Reg. No. of 
sending/receiving 
facility 
DISPOSAL 
DETAILS 
Specify method 
used 
30.1.13 HC001  Not applicable Autoclave 
27.2.13 HC002  Not applicable Autoclave 
14.3.13 HC003  Not applicable Autoclave 
6.7.13 HC004  Not applicable Autoclave 
13.11.13 HC005 4°C fridge plates Not applicable  
29.11.13 HC006 4°C fridge plates  
-80°C glycerol 
stock 
Not applicable  
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